SENISCA

Interested in our approach to skin rejuvenation? Come meet our VP Dermatology - Adam Clauss He is at the Biofilms Research Center for Biointerfaces Annual Workshop 2024 today and tomorrow at Malmö University and happy to talk about all things skin and SENISCA.

Our CEO, Sarah Cole, will be presenting! Come chat to Sarah to find out more about SENISCA and our award-winning therapeutic approaches.

Welcome Dr Alice Ghidini! Meet our new VP of Oligotherapeutics Development She has over 13 years of experience in RNA therapeutics, having trained in the labs of leading pioneers of the field (Karolinska, ETH, and Caltech). Alice continued her focus on RNA-based drug development in both pharmaceutical (AstraZeneca) and biotech settings (Sixfold Bioscience), where she was awarded a UKRI Future Leaders Fellowship for her work in oligonucleotide delivery design. Super excited for SENISCA to be guided forward with your expertise.

SENISCA won! Commercialisation project of the year - University of Exeter Knowledge Exchange Awards Thanks so much to the University, the Exeter Innovation team, all the sponsors and of course the judges. Super proud to be given this award and to wave the green UOE flag. #bleedgreen #winners #rnabiology #senescence #commercialisation #ExeKEAwards24

Interested in SENISCAs approach to age-related diseases? Meet our CDO Tim Sebastian Schmidt He'll be at the 3rd Annual Inhaled and Nasal Biologics/DNA forum in Cambridge later this week. Come chat about our progress in developing novel inhaled senomorphic oligonucleotides.

Our CSO is talking! Oligonucleotide Senotherapeutics for the Diseases of Ageing - Professor Lorna Harries Come chat with our CSO and CTO at the ATDbio symposium about our approach to address age-related diseases using oligonucleotides.

Our CSO, Lorna Harries, was recently quoted in Nature! Check out the details below:

I very much enjoyed the excellent presentations and discussion rounds on Oligonucleotide * design and synthesis, * delivery and bioavailability, * bioanalytical method development, * the increasing understanding in how to target the dark genome and how * AI can effectively be used in the above at the 4th Annual Oligonucleotide Therapeutics and Delivery Congress in London. Great to catch up!

We are proud to announce the appointment of @Tim Edwards as Chairman of the Board at SENISCA. Tim brings over 30 years of leadership experience in the life-sciences sector, during which he has played a major role in the development of several private and public biotechnology companies. He is currently Chair of Schroders Capital Global Innovation Trust, Storm Therapeutics Ltd, EndLyz Therapeutics Inc. and AstronauTx Ltd. His appointment reflects SENISCA’s continued growth, and his extensive knowledge of the sector and deep experience in guiding growth companies to their next stage of development will be invaluable to SENISCA as we continue our journey towards becoming a clinical stage novel senotherapeutics company for the treatment of age-related disease. Read more in the full press release here: https://lnkd.in/ekW9GShe #appointment #leadership #chairman #senescence

Dr. David Chiswell, Ph.D., OBE, 1953 - 2024 It is with great sadness that we pay tribute to our friend and former Chairman, Dr David Chiswell OBE, who sadly passed away in August after a short illness. Dave was a scientist, entrepreneur and one of the UK’s most successful biotechnology executives. Dave co-founded Cambridge Antibody Technology (CAT) in 1990 and served as its Chief Executive Officer from 1996 to 2002, taking CAT onto both the London Stock Exchange and Nasdaq. He also served as Chairman and then CEO of Kymab from 2015 to 2018. Amongst many other achievements, Dave was also Chairman of the UK BioIndustry Association. His major contributions to the industry were recognised with the award of an OBE by HM the Queen in 2006. Dave had a hugely positive impact in his role as Chairman at SENISCA and will be greatly missed by the whole team. Our thoughts are with his family and friends at this time.